clinical trial · NCT06849258
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
Rivermark Medical·N/A·recruiting·n = 215
Benign Prostatic HyperplasiaFloStentSham (Control)
brief summary
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.
started
Feb 10, 2025
primary completion
Dec 31, 2032
completion
Dec 31, 2032
last updated
Jun 11, 2026
official title
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol